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INTRODUCTION 
Depo-Provera (DMPA) is one of the progestin-only 
methods used for contraception. It was originally 
approved to treat endometriosis and certain cancers but 
is most commonly also used as a contraceptive [1].  A 
90-day dosage of 150 mg of DMPA has been associated 
with side effects, including irregular menstruation, 
anxiety, headaches, weakness, abdominal pain, weight 
gain and amenorrhoea [2]. However, the effect of 
DMPA in suppressing the adrenal cortex at a dose of 
150mg has never been reported before.  We report a 
case of a woman who had been on DMPA for 16 years 
and who developed symptoms of adrenal suppression.  
CASE PRESENTATION 
A 49-year old lady was referred by her General 
Practitioner for severe lethargy and generalized body 
pain during her attempt to stop her DMPA treatment.   
 
 
She is a working mother of 5, who was started on 
DMPA treatment following the birth of her last child 16 
years ago.  She has not been attending any regular 
follow-ups with her gynaecologist and obtained the 150 
mg three-monthly injections of DMPA from a nearby 
pharmacy. She has noted progressive weight gain of 
approximately 30kg within the past 10 years, which she 
attributed to poor dietary habits and sedentary lifestyle.  
She became amenorrheic after a year of treatment with 
occasional spotting. 
Five years ago, at the age of 44, she stopped 
taking the DMPA injection, following advice from her 
GP. However, a few weeks after stopping the DMPA 
she became severely lethargic, and suffered headaches 
and erratic mood swings, which subsequently led to her 
low mood.  She attributed her condition to the cessation 
of the DMPA and recommenced the injections, which 
immediately alleviated her symptoms and boosted her 
energy levels.  
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She has no other medical condition and denies taking 
any supplement or traditional medications.  
During her current presentation, she was still on 
DMPA injection to help her with her mood swings and 
energy levels.  She was however still complaining of 
occasional lethargy, headache, generalized body pains 
and mood swings but had expressed her wish to 
discontinue with her DMPA.  On clinical examination, 
she appeared plethoric with apparent moonlike-facies. 
There was acanthosis nigricans but no paper-thin skin, 
no striae, no bruising and no hirsutism. There was 
evidence of proximal myopathy, which was confined to 
the lower limbs.  Her weight was 110kg with a BMI of 
47 kg/m2.  Her blood pressure was 128/78 (sitting) and 
120/70 (standing) with a heart rate of 79 beats per 
minute. Chest and cardiovascular examination were 
unremarkable. Her abdomen was soft with no 
organomegaly. 
Laboratory investigations showed reduction in 
early morning cortisol level at 7am; 140 nmol/L 
(N=170-536 nmol/L).  Serum estradiol level was 
normal; 106.8 pmol/L (normal level: <18.4-183 
pmol/L) as well as progesterone, which was 0.9 nmol/L 
(normal level: 0.3-2.5 nmol/L).  However, her follicular 
stimulating hormone level was low at 8.76 IU/L (normal 
level: 26-135 IU/L). Similarly, her luteinizing hormone 
was also low at 2.92 IU/L (normal level: 7.7-59 IU/L). 
Renal profile and thyroid function test otherwise were 
normal.  
CT scan of the adrenal showed evidence of left 
adrenal incidentaloma - 0.9 x 0.9cm. HU (plain): 5-40 
(average 23), HU (portovenous): 100-150 (average 
125), HU (delayed): 35-55 (average 45) with absolute 
washout of 78% and relative washout 64%. 
DMPA was stopped for the second time and a 
short synacthen test was performed 3 months later and 
the results showed partial response of cortisol to 
synacthen = 0 hour: 156 nmol/L (normal value in 
morning 170-536 nmol/L), at 30 mins 384.9 nmol/L and 
at 60 min 429.7 nmol/L (N=increment >200nmol/L 
above baseline and peak >550 nmol/L. At this juncture, 
she was still complaining of lethargy and low mood. 
She was treated with low dose hydrocortisone 5 
mg bd for 1 year before it was stopped. At subsequent 
clinic follow up sessions, she appeared well, and denied 
any symptoms of hypo-cortisolism. Six months later, 
her short synacthen test was normal. She however does 
have occasional emotional lability and remains 
amenorheic. 
 
DISCUSSION 
The contraceptive effect of three monthly DMPA 
injections are due to its anti-oestrogenic, anti-
androgenic and anti-gonadotrophic actions, which 
prevent follicular maturation and ovulation and causes 
thickening of cervical mucus that inhibits sperm entry 
into the uterus [3].  
DMPA has been identified to have a notable 
cortisol-like glucocorticoid activity on the hypothalmic-
pituitary-adrenal (HPA) axis since the 1970s when 
patients on DMPA presented with cushingoid 
symptoms, such as weight gain, facial swelling and 
generalised edema [4].This cortisol-like effect is 
believed to exert a negative feedback action on the 
hypothalamus or the pituitary leading to low plasma 
ACTH, suppression of adrenal function and decreased 
cortisol secretion. Mild suppression of the hypothalmic-
pituitary-adrenal axis has been reported in 10 children 
who received 100-150mg per week of DMPA for the 
treatment of precocious puberty [4]. A study done by 
Hellman et al [5] showed a 76% reduction in plasma 
cortisol concentration in 12 breast cancer patients who 
were given weekly doses of 400, 700 or 1200 mg of 
DMPA for 6-24 months. Another study also showed 
partial adrenal suppression in postmenopausal women 
with disseminated breast cancer who received high 
doses of DMPA of up to 250 mg four times daily[6]. 
Patients who developed adrenal suppression following 
DMPA treatment were reported to be older and perhaps 
could be more sensitive to the anabolic effects of 
DMPA than other patients [7]. Malik et al [8] reported 
a case-study of eleven patients who had received 
DMPA following treatment for breast carcinoma and 
hypernephroma. The duration of DMPA therapy ranged 
from 6 to 90 months. Four of the eleven patients had 
low basal cortisol levels and subnormal responses to 
synacthen and two patients had a borderline response.  
Eight patients had ACTH levels at or below the 
detection limit of the assay.  
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To our knowledge, there have been no reports 
to date, on partial or complete adrenal suppression due 
to prolonged use of DMPA, particularly at a dose of 150 
mg when used as a contraceptive. Our patient presented 
with typical symptoms of hypo-cortisolism during the 
period of cessation of DMPA therapy.  This was 
confirmed by the presence of partial adrenal 
suppression following the synacthen test.  Her CT scan, 
which showed adrenal incidentaloma, highlights the 
likelihood that her condition was due to the DMPA 
therapy. This case highlights 2 major points, which 
differ from previous reports. The first being the 
prolonged and unsupervised use of the injectable drug 
and the second being that even at relatively low doses 
long-term usage of DMPA can lead to hypo-cortisolism.  
  
CONCLUSION 
Depo-Provera or DMPA has been associated with 
adrenal suppression due to cortisol-like glucocorticoid 
activity, which provides negative feedback effects on 
the hypothalamus or pituitary.  This results in low 
plasma ACTH levels and consequently also decreased 
plasma cortisol.  Our patient developed partial adrenal 
suppression due to prolonged, unsupervised 
prescription and use of a low dose DMPA.  Thus, 
clinicians should be wary of this insidious side effect of 
a very common drug even when used at low doses.   
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